Basic Stats
| CIK | 1782594 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Genetron Holdings Limited - Depositary Receipt (Common Stock)
SEC Filings (Chronological Order)
This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.
| April 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-39328 Genetron Holdings Limited (Exact name of registrant as specified in |
|
| April 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| April 1, 2024 |
SC 13D/A 1 tm2410221d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Genetron Holdings Limited (Name of Issuer) Ordinary shares, par value US$0.00002 per share (Title of Class of Securities) 37186H100** (CUSIP Number) Marc E. Binda Chief Financial Officer Alexandria Venture Invest |
|
| March 29, 2024 |
SC 13D/A 1 ea0202896-13da1tianjingene.htm AMENDMENT NO. 1 TO SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Genetron Holdings Limited (Name of Issuer) Ordinary Shares, par value US$0.00002 per share (Title of Class of Securities) 37186H209** (CUSIP Number) Johnson Huang 25th Floor and 26 |
|
| March 29, 2024 |
As filed with the United States Securities and Exchange Commission on March 29, 2024 As filed with the United States Securities and Exchange Commission on March 29, 2024 Registration No. |
|
| March 29, 2024 |
SC 13D/A 1 sc13da1.htm SCHEDULE 13D, AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Genetron Holdings Limited (Name of Issuer) Ordinary shares, par value $0.00002 per share (Title of Class of Securities) 37186H209** (CUSIP Number) Mr. Sizhen Wang FHP Holdings Limited c/o 1-2/F, Buildi |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2024 Commission File Number: 001-39328 Genetron Holdings Limited (Exact Name of Registrant as Specified in Its Charter) 1-2/F, Building 11, Zone 1 No.8 Life Science Parkway Changping Dist |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13E-3 (Amendment No. 3) RULE 13e-3 TRANSACTION STATEMENT (Pursuant to Section 13(e) of the Securities Exchange Act of 1934) Genetron Holdings Limited (Name of the Issuer) Genetron Holdings Limited New Genetron Holding Limited Genetron New Co Limited Mr. Sizhen Wang FHP Holdings Limited SUPER SAIL, LLC Genetron Discove |
|
| March 28, 2024 |
Genetron Health Announces Completion of Going Private Transaction Exhibit 99.1 Genetron Health Announces Completion of Going Private Transaction BEIJING, China, March 28, 2024 (GLOBE NEWSWIRE) — Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced to |
|
| February 21, 2024 |
Genetron Health Announces Shareholders’ Approval of Merger Agreement Exhibit 99.1 Genetron Health Announces Shareholders’ Approval of Merger Agreement BEIJING, China, February 21, 2024 (GLOBE NEWSWIRE) — Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announ |
|
| February 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2024 Commission File Number: 001-39328 Genetron Holdings Limited (Exact Name of Registrant as Specified in Its Charter) 1-2/F, Building 11, Zone 1 No.8 Life Science Parkway Changping D |
|
| January 17, 2024 |
Genetron Health to Hold Extraordinary General Meeting of Shareholders Exhibit 99.1 Genetron Health to Hold Extraordinary General Meeting of Shareholders BEIJING, China, January 17, 2024 (GLOBE NEWSWIRE) — Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announ |
|
| January 17, 2024 |
PROXY STATEMENT OF THE COMPANY TABLE OF CONTENTS Exhibit (a)-(1) PROXY STATEMENT OF THE COMPANY January 17, 2024 Shareholders of Genetron Holdings Limited: Re: Notice of Extraordinary General Meeting of Shareholders Dear Shareholder: You are cordially invited to attend an extraordinary general meeting of shareholders of Genetron Holdings Limited, an exempted company with limited liability incorporated under the laws of the Cayman Islands (the “Company”), to be held on February 21, 2024 at 9:00 a. |
|
| January 17, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13E-3 (Amendment No. 2) RULE 13e-3 TRANSACTION STATEMENT (Pursuant to Section 13(e) of the Securities Exchange Act of 1934) Genetron Holdings Limited (Name of the Issuer) Genetron Holdings Limited New Genetron Holding Limited Genetron New Co Limited Mr. Sizhen Wang FHP Holdings Limited SUPER SAIL, LL |
|
| January 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2024 Commission File Number: 001-39328 Genetron Holdings Limited (Exact Name of Registrant as Specified in Its Charter) 1-2/F, Building 11, Zone 1 No.8 Life Science Parkway Changping Di |
|
| January 5, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13E-3 (Amendment No. 1) RULE 13e-3 TRANSACTION STATEMENT (Pursuant to Section 13(e) of the Securities Exchange Act of 1934) Genetron Holdings Limited (Name of the Issuer) Genetron Holdings Limited New Genetron Holding Limited Genetron New Co Limited Mr. Sizhen Wang FHP Holdings Limited SUPER SAIL, LL |
|
| January 5, 2024 |
PRELIMINARY PROXY STATEMENT OF THE COMPANY TABLE OF CONTENTS Exhibit (a)-(1) PRELIMINARY PROXY STATEMENT OF THE COMPANY Shareholders of Genetron Holdings Limited: Re: Notice of Extraordinary General Meeting of Shareholders Dear Shareholder: You are cordially invited to attend an extraordinary general meeting of shareholders of Genetron Holdings Limited, an exempted company with limited liability incorporated under the laws of the Cayman Islands (the “Company”), to be held on at a. |
|
| January 5, 2024 |
Davis Polk & Wardwell Hong Kong Solicitors The Hong Kong Club Building 3A Chater Road Hong Kong China January 5, 2024 Re: Genetron Holdings Limited Schedule 13E-3 filed November 27, 2023 Filed by Genetron Holdings Limited et al. |
|
| November 27, 2023 |
[Remainder of page intentionally left blank] Exhibit (D)(8) Execution Version October 11, 2023 New Genetron Holding Limited (“Parent”) ICS Corporate Services (Cayman) Limited, 3-212 Governors Square, 23 Lime Tree Bay Avenue P. |
|
| November 27, 2023 |
Exhibit (D)(13) Execution Version LIMITED GUARANTEE This Limited Guarantee (this “Limited Guarantee”), dated as of October 11, 2023, is made by CCB (Beijing) Investment Fund Management Co. |
|
| November 27, 2023 |
Exhibit (C)(2) Genetron Holdings Limited Private and Confidential The information contained herein is of a confidential nature and is intended for the exclusive use of the persons or firm to whom it is furnished by us. |
|
| November 27, 2023 |
PRELIMINARY PROXY STATEMENT OF THE COMPANY TABLE OF CONTENTS Exhibit (a)-(1) PRELIMINARY PROXY STATEMENT OF THE COMPANY Shareholders of Genetron Holdings Limited: Re: Notice of Extraordinary General Meeting of Shareholders Dear Shareholder: You are cordially invited to attend an extraordinary general meeting of shareholders of Genetron Holdings Limited, an exempted company with limited liability incorporated under the laws of the Cayman Islands (the “Company”), to be held on at a. |
|
| November 27, 2023 |
Exhibit (D)(12) Execution Version LIMITED GUARANTEE This Limited Guarantee (this “Limited Guarantee”), dated as of October 11, 2023, is made by Wuxi Huihongyingkang Investment Partnership (Limited Partnership), a limited partnership organized under the laws of the PRC (the “Guarantor”), in favor of Genetron Health (Beijing) Co. |
|
| November 27, 2023 |
Exhibit (D)(14) Execution Version LIMITED GUARANTEE This Limited Guarantee (this “Limited Guarantee”), dated as of October 11, 2023, is made by Wealth Strategy Holding Limited, a company incorporated under the laws of the Hong Kong SAR (the “Guarantor”), in favor of Genetron Holdings Limited, an exempted company with limited liability incorporated under the laws of the Cayman Islands (the “Guaranteed Party”). |
|
| November 27, 2023 |
[Remainder of page intentionally left blank] Exhibit (D)(5) Execution Version October 11, 2023 New Genetron Holding Limited (“Parent”) ICS Corporate Services (Cayman) Limited, 3-212 Governors Square, 23 Lime Tree Bay Avenue P. |
|
| November 27, 2023 |
[Remainder of page intentionally left blank] Exhibit (D)(6) Execution Version October 11, 2023 New Genetron Holding Limited (“Parent”) ICS Corporate Services (Cayman) Limited, 3-212 Governors Square, 23 Lime Tree Bay Avenue P. |
|
| November 27, 2023 |
[Remainder of page intentionally left blank] Exhibit (D)(7) Execution Version October 11, 2023 New Genetron Holding Limited (“Parent”) ICS Corporate Services (Cayman) Limited, 3-212 Governors Square, 23 Lime Tree Bay Avenue P. |
|
| November 27, 2023 |
Exhibit (D)(11) Execution Version LIMITED GUARANTEE This Limited Guarantee (this “Limited Guarantee”), dated as of October 11, 2023, is made by Surrich International Company Limited, a company incorporated under the laws of the Hong Kong SAR (the “Guarantor”), in favor of Genetron Holdings Limited, an exempted company with limited liability incorporated under the laws of the Cayman Islands (the “Guaranteed Party”). |
|
| November 27, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Schedule 13E-3 (Form Type) GENETRON HOLDINGS LIMITED (Name of the Issuer and Name of Person Filing Statement) Table 1 – Transaction Valuation Transaction Valuation Fee Rate Amount of Filing Fee Fees to Be Paid $ 50,945,189. |
|
| November 27, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13E-3 RULE 13e-3 TRANSACTION STATEMENT (Pursuant to Section 13(e) of the Securities Exchange Act of 1934) Genetron Holdings Limited (Name of the Issuer) Genetron Holdings Limited New Genetron Holding Limited Genetron New Co Limited Mr. Sizhen Wang FHP Holdings Limited SUPER SAIL, LLC Genetron Discove |
|
| October 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2023 Commission File Number: 001-39328 Genetron Holdings Limited (Exact Name of Registrant as Specified in Its Charter) 1-2/F, Building 11, Zone 1 No.8 Life Science Parkway Changping Di |
|
| October 24, 2023 |
GTH / Genetron Holdings Ltd - ADR / Wealth Strategy Group Ltd - SC 13D Activist Investment SC 13D 1 tm2328986-1sc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Genetron Holdings Limited (Name of Issuer) Ordinary shares, par value $0.00002 per share (Title of Class of Securities) 37186H100** (CUSIP Number) Ken Tsang Wealth Strategy Group Limited Easy Benefit Investment Limited |
|
| October 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Genetron Holdings Limited (Name of Issuer) Ordinary shares, par value US$0.00002 per share (Title of Class of Securities) 37186H100** (CUSIP Number) Marc E. Binda Chief Financial Officer Alexandria Venture Investments, LLC 26 North Euclid Avenue Pasadena, |
|
| October 20, 2023 |
GTH / Genetron Holdings Ltd - ADR / Wang Sizhen - SCHEDULE 13D Activist Investment SC 13D 1 sc13d.htm SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Genetron Holdings Limited (Name of Issuer) Ordinary shares, par value $0.00002 per share (Title of Class of Securities) 37186H100** (CUSIP Number) Mr. Sizhen Wang FHP Holdings Limited c/o 1-2/F, Building 11, Zone 1, No. 8 L |
|
| October 20, 2023 |
SC 13D 1 tm2328858d1sc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Genetron Holdings Limited (Name of Issuer) Ordinary shares, par value $0.00002 per share (Title of Class of Securities) 37186H100** 37186H209*** (CUSIP Number) New Genetron Holding Limited Tianjin Genetron Jun’an Busin |
|
| October 20, 2023 |
[Remainder of page intentionally left blank] EX-99.5 5 ea186715ex99-5genetron.htm EQUITY COMMITMENT LETTER DATED OCTOBER 11, 2023 BETWEEN TIANJIN KANGYUE BUSINESS MANAGEMENT PARTNERSHIP (LIMITED PARTNERSHIP) AND NEW GENETRON HOLDING LIMITED Exhibit 5 Execution Version October 11, 2023 New Genetron Holding Limited (“Parent”) ICS Corporate Services (Cayman) Limited, 3-212 Governors Square, 23 Lime Tree Bay Avenue P.O. Box 30746, Seven Mile Bea |
|
| October 20, 2023 |
EX-99.(D) 4 tm2328858d1ex99-d.htm EXHIBIT D Exhibit D Execution Version INTERIM INVESTOR AGREEMENT This Interim Investor Agreement (the “Agreement”) is made as of October 11, 2023 by and among Mr. Sizhen Wang (the “Founder”), Tianjin Kangyue Business Management Partnership (Limited Partnership) (“Tianjin Kangyue”), CICC Healthcare Investment Fund, L.P. (“CICC Healthcare,” and together with Tianjin |
|
| October 20, 2023 |
ROLLOVER AND SUPPORT AGREEMENT EX-99 3 exc.htm EXHIBIT C - ROLLOVER AND SUPPORT AGREEMENT Exhibit C Execution Version ROLLOVER AND SUPPORT AGREEMENT This ROLLOVER AND SUPPORT AGREEMENT (this “Agreement”) is entered into as of October 11, 2023 by and between New Genetron Holding Limited, an exempted company with limited liability incorporated under the Laws of the Cayman Islands (“Parent”) and the persons set forth on Schedule A |
|
| October 20, 2023 |
EX-99 2 exa.htm EXHIBIT A - JOINT FILING AGREEMENT Exhibit A JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, each of the undersigned hereby agrees to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the ordinary shares of Genetron Holdings Limited, and that this Ag |
|
| October 20, 2023 |
EX-99.1 2 ea186715ex99-1genetron.htm JOINT FILING AGREEMENT, DATED OCTOBER 20, 2023 Exhibit 1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, each of the undersigned parties hereby agree to file jointly the statement on Schedule 13D (including any amendments thereto) with respect to the Ordinary Shares, par value $0.00002 per share, |
|
| October 20, 2023 |
EX-99.8 8 ea186715ex99-8genetron.htm LIMITED GUARANTEE DATED OCTOBER 11, 2023 ISSUED AND DELIVERED BY CICC HEALTHCARE INVESTMENT FUND, L.P Exhibit 8 Execution Version LIMITED GUARANTEE This Limited Guarantee (this “Limited Guarantee”), dated as of October 11, 2023, is made by CICC Healthcare Investment Fund, L.P., a partnership organized under the laws of Cayman Islands (the “Guarantor”), in favor |
|
| October 20, 2023 |
EX-99.3 3 ea186715ex99-3genetron.htm INTERIM INVESTORS AGREEMENT DATED OCTOBER 11, 2023 Exhibit 3 Execution Version INTERIM INVESTOR AGREEMENT This Interim Investor Agreement (the “Agreement”) is made as of October 11, 2023 by and among Mr. Sizhen Wang (the “Founder”), Tianjin Kangyue Business Management Partnership (Limited Partnership) (“Tianjin Kangyue”), CICC Healthcare Investment Fund, L.P. ( |
|
| October 20, 2023 |
EX-99 4 exd.htm EXHIBIT D - INTERIM INVESTOR AGREEMENT Exhibit D Execution Version INTERIM INVESTOR AGREEMENT This Interim Investor Agreement (the “Agreement”) is made as of October 11, 2023 by and among Mr. Sizhen Wang (the “Founder”), Tianjin Kangyue Business Management Partnership (Limited Partnership) (“Tianjin Kangyue”), CICC Healthcare Investment Fund, L.P. (“CICC Healthcare,” and together w |
|
| October 20, 2023 |
SC 13D 1 ea186715-13dtianjingenetron.htm SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Genetron Holdings Limited (Name of Issuer) Ordinary Shares, par value US$0.00002 per share (Title of Class of Securities) 37186H100** (CUSIP Number) Johnson Huang 25th Floor and 26th Floor, China World |
|
| October 20, 2023 |
ROLLOVER AND SUPPORT AGREEMENT EX-99.(C) 3 tm2328858d1ex99-c.htm EXHIBIT C Exhibit C Execution Version ROLLOVER AND SUPPORT AGREEMENT This ROLLOVER AND SUPPORT AGREEMENT (this “Agreement”) is entered into as of October 11, 2023 by and between New Genetron Holding Limited, an exempted company with limited liability incorporated under the Laws of the Cayman Islands (“Parent”) and the persons set forth on Schedule A hereto (each, |
|
| October 20, 2023 |
ROLLOVER AND SUPPORT AGREEMENT EX-99.4 4 ea186715ex99-4genetron.htm ROLLOVER AND SUPPORT AGREEMENT DATED OCTOBER 11, 2023 Exhibit 4 Execution Version ROLLOVER AND SUPPORT AGREEMENT This ROLLOVER AND SUPPORT AGREEMENT (this “Agreement”) is entered into as of October 11, 2023 by and between New Genetron Holding Limited, an exempted company with limited liability incorporated under the Laws of the Cayman Islands (“Parent”) and the |
|
| October 20, 2023 |
[Remainder of page intentionally left blank] EX-99.6 6 ea186715ex99-6genetron.htm EQUITY COMMITMENT LETTER DATED OCTOBER 11, 2023 BETWEEN CICC HEALTHCARE INVESTMENT FUND, L.P. AND NEW GENETRON HOLDING LIMITED Exhibit 6 Execution Version October 11, 2023 New Genetron Holding Limited (“Parent”) ICS Corporate Services (Cayman) Limited, 3-212 Governors Square, 23 Lime Tree Bay Avenue P.O. Box 30746, Seven Mile Beach, Grand Cayman KY1-1203, Cayma |
|
| October 20, 2023 |
EX-99.7 7 ea186715ex99-7genetron.htm LIMITED GUARANTEE DATED OCTOBER 11, 2023 ISSUED AND DELIVERED BY TIANJIN KANGYUE BUSINESS MANAGEMENT PARTNERSHIP (LIMITED PARTNERSHIP) Exhibit 7 Execution Version LIMITED GUARANTEE This Limited Guarantee (this “Limited Guarantee”), dated as of October 11, 2023, is made by Tianjin Kangyue Business Management Partnership (Limited Partnership), a limited partnersh |
|
| October 20, 2023 |
EX-99.(A) 2 tm2328858d1ex99-a.htm EXHIBIT A Exhibit A JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, each of the undersigned hereby agrees to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the ordinary shares of Genetron Holdings Limited, and that this Agreement |
|
| October 19, 2023 |
ROLLOVER AND SUPPORT AGREEMENT EX-99.3 3 ea186991ex99-3genetron.htm ROLLOVER AND SUPPORT AGREEMENT, DATED AS OF OCTOBER 11, 2023 Exhibit 99.3 Execution Version ROLLOVER AND SUPPORT AGREEMENT This ROLLOVER AND SUPPORT AGREEMENT (this “Agreement”) is entered into as of October 11, 2023 by and between New Genetron Holding Limited, an exempted company with limited liability incorporated under the Laws of the Cayman Islands (“Parent |
|
| October 19, 2023 |
GTH / Genetron Holdings Ltd - ADR / Vivo Capital IX, LLC - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| October 19, 2023 |
EX-99.1 2 ea186991ex99-1genetron.htm JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT This will confirm the agreement by and among the undersigned that the Schedule 13D filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the Ordinary shares, par value $0.00002 of Genetron Holdings Limited, is being f |
|
| October 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2023 Commission File Number: 001-39328 Genetron Holdings Limited (Exact Name of Registrant as Specified in Its Charter) 1-2/F, Building 11, Zone 1 No.8 Life Science Parkway Changping Di |
|
| October 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2023 Commission File Number: 001-39328 Genetron Holdings Limited (Exact Name of Registrant as Specified in Its Charter) 1-2/F, Building 11, Zone 1 No.8 Life Science Parkway Changping Di |
|
| October 11, 2023 |
Genetron Health Enters into Definitive Merger Agreement for Going Private Transaction Exhibit 99.1 Genetron Health Enters into Definitive Merger Agreement for Going Private Transaction BEIJING, China, October 11, 2023 (GLOBE NEWSWIRE) — Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics dev |
|
| October 11, 2023 |
Exhibit 99.2 Execution Version AGREEMENT AND PLAN OF MERGER among New Genetron Holding Limited, GENETRON NEW CO LIMITED and GENETRON HOLDINGS LIMITED 泛生子基因(控股)有限公司 Dated as of October 11, 2023 TABLE OF CONTENTS Page Article I THE MERGER 2 Section 1.01 The Merger 2 Section 1.02 Closing; Closing Date 2 Section 1.03 Effective Time 3 Section 1.04 Effects of the Merger 3 Section 1.05 Governin |
|
| September 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2023 Commission File Number: 001-39328 Genetron Holdings Limited (Exact Name of Registrant as Specified in Its Charter) 1-2/F, Building 11, Zone 1 No.8 Life Science Parkway Changping |
|
| September 5, 2023 |
Genetron Holdings Limited 1-2/F, Building 11, Zone 1 No. 8 Life Science Parkway Changping District, Beijing, 102206 People’s Republic of China September 5, 2023 VIA EDGAR Mr. Jimmy McNamara Ms. Jennifer Thompson Division of Corporation Finance Disclosure Review Program U.S. Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 USA RE: Genetron Holdings Ltd Form 20-F for the Year |
|
| May 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2023 Commission File Number: 001-39328 Genetron Holdings Limited (Exact Name of Registrant as Specified in Its Charter) 1-2/F, Building 11, Zone 1 No.8 Life Science Parkway Changping Distri |
|
| May 23, 2023 |
Genetron Health Announces Receipt of Notification from Nasdaq Exhibit 99.1 Genetron Health Announces Receipt of Notification from Nasdaq BEIJING, China, May 23, 2023 (GLOBAL NEWSWIRE) - Genetron Holdings Limited ("Genetron Health" or the "Company", NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced t |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(B) OR 12(G) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022. OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF |
|
| May 12, 2023 |
EX-15.4 11 gth-20221231xex15d4.htm EXHIBIT 15.4 Exhibit 15.4 May 12, 2023 VIA EDGAR Division of Corporation Finance U.S. Securities & Exchange Commission 100 F Street, NE Washington, D.C. 20549 Re: Genetron Holdings Limited Submission under the Item 16I(a) of Form 20-F Attn: Division of Corporation Finance Office of Industrial Applications and Services Dear Sir/Madam, In compliance with the Holdin |
|
| May 12, 2023 |
Exhibit 2.7 Description of rights of each class of securities registered under Section 12 of the Securities Exchange Act of 1934 (the “Exchange Act”) American Depositary Shares (“ADSs”) each representing five ordinary shares of Genetron Holdings Limited (“we,” “our,” “our company,” or “us”) are listed and traded on The Nasdaq Global Market (“Nasdaq”) and, in connection therewith, the ordinary shar |
|
| May 12, 2023 |
Consent of PricewaterhouseCoopers Zhong Tian LLP, Independent Registered Public Accounting Firm EX-15.1 8 gth-20221231xex15d1.htm EXHIBIT 15.1 Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (No. 333-252371) of Genetron Holdings Limited of our report dated May 12, 2023 relating to the financial statements and the effectiveness of internal control over financial reporting, which |
|
| May 12, 2023 |
EX-15.3 10 gth-20221231xex15d3.htm EXHIBIT 15.3 Exhibit 15.3 May 12, 2023 To: Genetron Holdings Limited (泛生子基因(控股)有限公司) 1-2/F, Building 11, Zone 1 No.8 Life Science Parkway Changping District, Beijing People’s Republic of China Dear Sirs/Madams, We hereby consent to the reference to our firm under the heading “Explanatory Note”, “Item 3. Key Information – D. Risk Factors - Risks Related to Our Bus |
|
| May 12, 2023 |
Exhibit 13.1 Certification by the Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Genetron Holdings Limited (the “Company”) on Form 20-F for the year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Sizhen Wang, Chief Executive Officer of the Company, cert |
|
| May 12, 2023 |
Exhibit 12.2 Certification by the Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Evan Ce Xu, certify that: 1.I have reviewed this annual report on Form 20-F of Genetron Holdings Limited (the “company”); 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statem |
|
| May 12, 2023 |
Exhibit 12.1 Certification by the Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Sizhen Wang, certify that: 1.I have reviewed this annual report on Form 20-F of Genetron Holdings Limited (the “company”); 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the state |
|
| May 12, 2023 |
Exhibit 13.2 Certification by the Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Genetron Holdings Limited (the “Company”) on Form 20-F for the year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Evan Ce Xu, Chief Financial Officer of the Company, certi |
|
| May 12, 2023 |
Consent of Walkers (Hong Kong) Exhibit 15.2 Partners: John Cartwright Audrey Coker Joanne Collett Mark Cummings Colm Dawson James Gaden Thomas Granger Kristen Kwok Wing Lam William Lee Thomas Pugh Andrew Randall Rupen Shah Colette Wilkins KC Denise Wong * * * ***** *** **** ** ** * * ***** ** ***** *** ** May 12, 2023 NASD/BLUI/G3359-H22357 Genetron Holdings Limited 泛生子基因(控股)有限公司 Walkers Corporate Limited 190 Elgin Avenue Georg |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Checkone) : ¨ Form 10-K x Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D ¨ Form N-CEN ¨ Form N-CSR For Period Ended: December 31, 2022 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on Form 10-Q For the Transition Pe |
|
| February 14, 2023 |
SC 13G/A 1 sc13ga2.htm SCHEDULE 13G/A - AMENDMENT NO. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.2)* Genetron Holdings Limited (Name of Issuer) Ordinary shares, par value US$0.00002 per share (Title of Class of Securities) 37186H100** (CUSIP Number) December 31, 2022 (Date of Event which Requires |
|
| January 18, 2023 |
6-K 1 tm233748d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2023 Commission File Number: 001-39328 Genetron Holdings Limited (Exact Name of Registrant as Specified in Its Charter) 1-2/F, Building 11, Zone 1 No.8 L |
|
| January 18, 2023 |
Genetron health REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT Exhibit 99.1 Genetron health REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT BEIJING, China, January 18, 2023 (GLOBE NEWSWIRE) - Genetron Holdings Limited ("Genetron Health" or the "Company", NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, |
|
| November 3, 2022 |
November 3, 2022 Re: Genetron Holdings Limited Annual Report on Form 20-F Response dated September 30, 2022 File No. |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2022 Commission File Number: 001-39328 Genetron Holdings Limited (Exact Name of Registrant as Specified in Its Charter) 1-2/F, Building 11, Zone 1 No.8 Life Science Parkway Changping D |
|
| October 12, 2022 |
Exhibit 99.1 Genetron Health Reports Unaudited Second Quarter 2022 Financial Results BEIJING, China, October 12, 2022 ? Genetron Holdings Limited ("Genetron Health" or the "Company", NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today reported its un |
|
| October 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2022 Commission File Number: 001-39328 Genetron Holdings Limited (Exact Name of Registrant as Specified in Its Charter) 1-2/F, Building 11, Zone 1 No.8 Life Science Parkway Changping Di |
|
| September 30, 2022 |
September 30, 2022 Re: Genetron Holdings Limited Annual Report on Form 20-F Filed April 29, 2022 File No. |
|
| September 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2022 Commission File Number: 001-39328 Genetron Holdings Limited (Exact Name of Registrant as Specified in Its Charter) 1-2/F, Building 11, Zone 1 No.8 Life Science Parkway Changping |
|
| September 2, 2022 |
Exhibit 99.1 Genetron Health Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee BEIJING, China, September 2, 2022 ? Genetron Holdings Limited (?Genetron Health? or the ?Company?, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion dia |
|
| August 22, 2022 |
Genetron Health Announces Receipt of a Preliminary Non-Binding Proposal to Acquire the Company Exhibit 99.1 Genetron Health Announces Receipt of a Preliminary Non-Binding Proposal to Acquire the Company BEIJING, China, August 22, 2022 ? Genetron Holdings Limited (?Genetron Health? or the ?Company?, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, |
|
| August 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2022 Commission File Number: 001-39328 Genetron Holdings Limited (Exact Name of Registrant as Specified in Its Charter) 1-2/F, Building 11, Zone 1 No.8 Life Science Parkway Changping Dis |
|
| June 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2022 Commission File Number: 001-39328 Genetron Holdings Limited (Exact Name of Registrant as Specified in Its Charter) 1-2/F, Building 11, Zone 1 No.8 Life Science Parkway Changping Distr |
|
| June 2, 2022 |
Genetron Health Reports Unaudited First Quarter 2022 Financial Results Exhibit 99.1 Genetron Health Reports Unaudited First Quarter 2022 Financial Results BEIJING, China, June 2, 2022 ? Genetron Holdings Limited (?Genetron Health? or the ?Company?, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today reported its unaudit |
|
| April 29, 2022 |
Exhibit 15.3 ? April 29, 2022 ? To: Genetron Holdings Limited (?????(??)????) 1-2/F, Building 11, Zone 1 No.8 Life Science Parkway Changping District, Beijing People?s Republic of China Dear Sirs/Madams, We hereby consent to the reference to our firm under the heading ?Item 3. Key Information ? D. Risk Factors - Risks Related to Our Business and Industry?, ?Item 3. Key Information ? D. Risk Factor |
|
| April 29, 2022 |
Exhibit 13.1 Certification by the Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Genetron Holdings Limited (the “Company”) on Form 20-F for the year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Sizhen Wang, Chief Executive Officer of the Company, cert |
|
| April 29, 2022 |
Consent of PricewaterhouseCoopers Zhong Tian LLP, Independent Registered Public Accounting Firm Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (No. 333-252371) of Genetron Holdings Limited of our report dated April 29, 2022 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 20-F. /s/ Pricewaterhou |
|
| April 29, 2022 |
Exhibit 13.2 Certification by the Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Genetron Holdings Limited (the “Company”) on Form 20-F for the year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Evan Ce Xu, Chief Financial Officer of the Company, certi |
|
| April 29, 2022 |
Exhibit 12.1 Certification by the Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Sizhen Wang, certify that: 1. I have reviewed this annual report on Form 20-F of Genetron Holdings Limited (the ?company?); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the sta |
|
| April 29, 2022 |
Consent of Walkers (Hong Kong) EX-15.2 8 gth-20211231xex15d2.htm EXHIBIT 15.2 Exhibit 15.2 Partners: Paul Aherne ** John Cartwright * Joanne Collett * 29 April 2022 NASD/BLUI/G3359-H22357 Mark Cummings ******* Stuart D'Addona **** Nicholas Davies *** Genetron Holdings Limited 泛生子基因(控股)有限公司 Shamar Ennis *** Walkers Corporate Limited James Gaden **** 190 Elgin Avenue Thomas Granger ** George Town Kristen Kwok ** Grand Cayman KY1- |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 29, 2022 |
Exhibit 12.2 Certification by the Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Evan Ce Xu, certify that: 1. I have reviewed this annual report on Form 20-F of Genetron Holdings Limited (the “company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the stat |
|
| March 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2022 Commission File Number: 001-39328 Genetron Holdings Limited (Exact Name of Registrant as Specified in Its Charter) 1-2/F, Building 11, Zone 1 No.8 Life Science Parkway Changping Dist |
|
| March 29, 2022 |
Genetron Health Announces Unaudited Fourth Quarter and Full Year 2021 Financial Results Exhibit 99.1 Genetron Health Announces Unaudited Fourth Quarter and Full Year 2021 Financial Results BEIJING, China, March 29, 2022 ? Genetron Holdings Limited (?Genetron Health? or the ?Company?, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today a |
|
| March 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No )* Genetron Holdings Limited (Name of Issuer) Ordinary shares, par value US$0.00002 per share (Title of Class of Securities) 37186H100** (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to desi |
|
| March 14, 2022 |
Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that they are filing jointly pursuant to Rule 13-d-1(k)(1) of the Securities Exchange Act of 1934, as amended, with respect to ordinary shares of Genetron Holdings Limited, and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessity of filing additional |
|
| February 14, 2022 |
GTH / Genetron Holdings Limited ADS / Yan Hai - FORM SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.1)* Genetron Holdings Limited (Name of Issuer) Ordinary shares, par value US$0.00002 per share (Title of Class of Securities) 37186H100** (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to d |
|
| February 14, 2022 |
GTH / Genetron Holdings Limited ADS / Wang Sizhen - FORM SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Genetron Holdings Limited (Name of Issuer) Ordinary shares, par value US$0.00002 per share (Title of Class of Securities) 37186H100** (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Genetron Holdings Limited (Name of Issuer) Ordinary shares, par value US$0.00002 per share (Title of Class of Securities) 37186H100** (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to |
|
| January 10, 2022 |
Genetron Health Reiterates Full Year 2021 Revenue Guidance Exhibit 99.1 Genetron Health Reiterates Full Year 2021 Revenue Guidance BEIJING, January 10, 2022 ? Genetron Holdings Limited (?Genetron Health? or the ?Company?, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today reiterated its full year 2021 reven |
|
| January 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2022 Commission File Number: 001-39328 Genetron Holdings Limited (Exact Name of Registrant as Specified in Its Charter) 1-2/F, Building 11, Zone 1 No.8 Life Science Parkway Changping Di |
|
| November 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2021 Commission File Number: 001-39328 Genetron Holdings Limited (Exact Name of Registrant as Specified in Its Charter) 1-2/F, Building 11, Zone 1 No.8 Life Science Parkway Changping D |
|
| November 30, 2021 |
Genetron Health Reports Third Quarter 2021 Unaudited Financial Results Exhibit 99.2 Genetron Health Reports Third Quarter 2021 Unaudited Financial Results BEIJING, China, November 30, 2021 ? Genetron Holdings Limited (?Genetron Health? or the ?Company?, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today reported its un |
|
| November 30, 2021 |
Exhibit 99.1 Genetron Health Announces Co-Development Agreement with AstraZeneca R&D China for Personalized MRD Tests for Solid Tumors in China Collaboration highlights the value of MRD solid tumor data generated by Genetron?s Mutation Capsule platform, and further accelerates product development BEIJING, November 30, 2021 (GLOBE NEWSWIRE) ? Genetron Holdings Limited (?Genetron Health? or the ?Com |
|
| August 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2021 Commission File Number: 001-39328 Genetron Holdings Limited (Exact Name of Registrant as Specified in Its Charter) 1-2/F, Building 11, Zone 1 No.8 Life Science Parkway Changping Dis |
|
| August 24, 2021 |
Genetron Health Reports Second Quarter 2021 Unaudited Financial Results Exhibit 99.1 Genetron Health Reports Second Quarter 2021 Unaudited Financial Results BEIJING, China, August 24, 2021 ? Genetron Holdings Limited (?Genetron Health? or the ?Company?, NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced its una |
|
| June 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2021 Commission File Number: 001-39328 Genetron Holdings Limited (Exact Name of Registrant as Specified in Its Charter) 1-2/F, Building 11, Zone 1 No.8 Life Science Parkway Changping Distr |
|
| May 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2021 Commission File Number: 001-39328 Genetron Holdings Limited (Exact Name of Registrant as Specified in Its Charter) 1-2/F, Building 11, Zone 1 No.8 Life Science Parkway Changping Distri |
|
| May 24, 2021 |
Genetron Health Reports First Quarter 2021 Unaudited Financial Results Exhibit 99.1 Genetron Health Reports First Quarter 2021 Unaudited Financial Results BEIJING, China, May 24, 2021 ? Genetron Holdings Limited (?Genetron Health? or the ?Company?, NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced its unaudit |
|
| April 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Genetron Holdings Limited (Name of Issuer) Ordinary shares, par value US$0.00002 per share (Title of Class of Securities) 37186H100** (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of the Statement) Check the appropriate box to desig |
|
| April 9, 2021 |
Consent of Walkers (Hong Kong) Exhibit 15.2 Partners: Paul Aherne Joanne Collett Mark Cummings Stuart D?Addona Nicholas Davies Shamar Ennis James Gaden Kristen Kwok Jo Lit Callum McNeil Alice Molan Andrew Randall Rupen Shah Denise Wong ** * ***** **** *** *** **** ** * ** ****** ** ******* ** 9 April 2021 Genetron Holdings Limited ?????(??)???? Walkers Corporate Limited 190 Elgin Avenue George Town Grand Cayman KY1-9008 Cayman |
|
| April 9, 2021 |
Consent of PricewaterhouseCoopers Zhong Tian LLP, Independent Registered Public Accounting Firm Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (No. 333- 252371) of Genetron Holdings Limited of our report dated April 9, 2021 relating to the financial statements, which appears in this Form 20-F. /s/ PricewaterhouseCoopers Zhong Tian LLP Beijing, the People?s Republic of China Ap |
|
| April 9, 2021 |
Exhibit 13.2 CERTIFICATION BY PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Genetron Holdings Limited (the ?Company?) on Form 20-F for the year ended December 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the ?Report?), I, Evan Ce Xu, Chief Financial Officer, certify, pursuant to 18 |
|
| April 9, 2021 |
Exhibit 4.26 *** CERTAIN MATERIAL (INDICATED BY THREE ASTERISKS IN BRACKETS) HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH (1) NOT MATERIAL AND (2) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Investment Agreement with respect to Genetron Health?s Project of Precision Medicine Platform for Cancer Early Screening between Management Committee of Jiangsu Wuxi Huishan Economic Develo |
|
| April 9, 2021 |
Exhibit 13.1 CERTIFICATION BY PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Genetron Holdings Limited (the ?Company?) on Form 20-F for the year ended December 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the ?Report?), I, Sizhen Wang, Chief Executive Officer, certify, pursuant to 1 |
|
| April 9, 2021 |
Exhibit 12.1 CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Sizhen Wang, certify that: 1. I have reviewed this annual report on Form 20-F of Genetron Holdings Limited (the ?Company?); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the sta |
|
| April 9, 2021 |
Exhibit 12.2 CERTIFICATION BY PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Evan Ce Xu, certify that: 1. I have reviewed this annual report on Form 20-F of Genetron Holdings Limited (the ?Company?); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statemen |
|
| April 9, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(B) OR 12(G) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020. OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) |
|
| April 9, 2021 |
Exhibit 4.32 Spouse Consent Letter To: Genetron (Wuxi) Business Management Co., Ltd. Whereas: 1. I, [***] (ID card/passport number: [***]), am the spouse of the natural person Wang Sizhen (ID card number: [***]). Wang Sizhen holds 90% equity of Genetron (Wuxi) Biotech Co., Ltd. (hereinafter referred to as ?Target Equity Interest?) 2. With respect to the aforementioned Target Equity Interest held b |
|
| April 9, 2021 |
Exhibit 4.33 Spouse Consent Letter To: Genetron (Wuxi) Business Management Co., Ltd. Whereas: 1. I, [***] (ID card/passport number: [***]), am the spouse of the natural person Jiao Yuchen (ID card number: [***]). Jiao Yuchen holds 10% equity of Genetron (Wuxi) Biotech Co., Ltd. (hereinafter referred to as ?Target Equity Interest?) 2. With respect to the aforementioned Target Equity Interest held b |
|
| April 9, 2021 |
Exhibit 4.31 Exclusive Option Agreement This Exclusive Option Agreement (this ?Agreement?) is executed by and among the following Parties on December 7, 2020 in Wuxi, Jiangsu, the People?s Republic of China (the ?PRC?): Party A: Genetron (Wuxi) Business Management Co., Ltd., a limited liability company, organized and existing under the laws of the PRC, with its address at Room 401, No. 1719-8 Huis |
|
| April 9, 2021 |
Exhibit 4.28 Exclusive Business Cooperation Agreement This Exclusive Business Cooperation Agreement (this ?Agreement?) is made and entered into by and between the following parties on December 7, 2020 in Wuxi, Jiangsu, the People?s Republic of China (?China? or the ?PRC?). Party A: Genetron (Wuxi) Business Management Co., Ltd. Address: Room 401, No. 1719-8 Huishan Avenue, Huishan Economic Developm |
|
| April 9, 2021 |
Exhibit 4.27 *** CERTAIN MATERIAL (INDICATED BY THREE ASTERISKS IN BRACKETS) HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH (1) NOT MATERIAL AND (2) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Strategic Cooperation Agreement with respect to Early Screening Product for Liver Cancer between Genetron Health (Beijing) Co. Ltd. and Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Janua |
|
| April 9, 2021 |
Exhibit 15.3 April 9, 2021 To: Genetron Holdings Limited (?????(??)????) 1-2/F, Building 11, Zone 1 No.8 Life Science Parkway Changping District, Beijing People?s Republic of China Dear Sirs/Madams, We hereby consent to the reference to our firm in Genetron Holdings Limited?s annual report on Form 20-F for the fiscal year ended December 31, 2020, which will be filed by Genetron Holdings Limited in |
|
| April 9, 2021 |
Exhibit 4.29 Shareholder Voting Rights Entrustment Agreement This Shareholder Voting Rights Entrustment Agreement (hereinafter referred to as the ?Agreement?) is signed among following Parties on December 7, 2020 in Wuxi, Jiangsu, the People?s Republic of China (the ?PRC?). Party A: Genetron (Wuxi) Business Management Co., Ltd., a limited liability company, organized and existing under the laws of |
|
| April 9, 2021 |
Exhibit 2.7 Description of rights of each class of securities registered under Section 12 of the Securities Exchange Act of 1934 (the ?Exchange Act?) American Depositary Shares (?ADSs?) each representing five ordinary shares of Genetron Holdings Limited (?we,? ?our,? ?our company,? or ?us?) are listed and traded on The Nasdaq Global Market (?Nasdaq?) and, in connection therewith, the ordinary shar |
|
| April 9, 2021 |
Exhibit 4.30 Equity Interest Pledge Agreement This Equity Interest Pledge Agreement (hereinafter referred to as this ?Agreement?) has been executed by and among the following parties on December 7, 2020 in Wuxi, Jiangsu: Party A: Genetron (Wuxi) Business Management Co., Ltd., a limited liability company, organized and existing under the laws of the PRC, with its address at Room 401, No. 1719-8 Hui |
|
| March 25, 2021 |
Exhibit 99.1 Genetron Health Reports Unaudited Fourth Quarter and Full Year 2020 Financial Results, and Provides 2021 Revenue Guidance BEIJING, China, March 25, 2021 ? Genetron Holdings Limited (?Genetron Health? or the ?Company?, NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion |
|
| March 25, 2021 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2021 Commission File Number: 001-39328 Genetron Holdings Limited (Exact Name of Registrant as Specified in Its Charter) 1-2/F, Building 11, Zone 1 No.8 Life Science Parkway Changping Dist |
|
| March 24, 2021 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2021 Commission File Number: 001-39328 Genetron Holdings Limited (Exact Name of Registrant as Specified in Its Charter) 1-2/F, Building 11, Zone 1 No.8 Life Science Parkway Changping Dist |
|
| March 24, 2021 |
Genetron Health Releases New Data Results of HCCscreen™ for Liver Cancer Early Screening in China Exhibit 99.1 Genetron Health Releases New Data Results of HCCscreen? for Liver Cancer Early Screening in China ? HCCscreenTM achieved 88% sensitivity and 93% specificity, compared with 71% and 95%, respectively, by ultrasound plus AFP. ? In early-stage patients, the sensitivities of HCCscreenTM are 85% (tumor size of <3cm) and 96% (3-5 cm). ? The Company plans to initiate an NMPA registrational tr |
|
| February 12, 2021 |
Joint Filing Agreement by and between the Reporting Persons, dated as of February 12, 2021 Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Genetron Holdings Limited (Name of Issuer) Ordinary shares, par value US$0.00002 per share (Title of Class of Securities) 37186H100** (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to desi |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Genetron Holdings Limited (Name of Issuer) Ordinary shares, par value US$0.00002 per share (Title of Class of Securities) 37186H100** (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to desi |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Genetron Holdings Limited (Name of Issuer) Ordinary shares, par value US$0.00002 per share (Title of Class of Securities) 37186H100** (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to desi |
|
| January 25, 2021 |
FORM S-8 As filed with the Securities and Exchange Commission on January 25, 2021 Registration No. |
|
| November 27, 2020 |
Current Report of Foreign Issuer - FORM 6-K Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2020 Commission File Number: 001-39328 Genetron Holdings Limited (Exact Name of Registrant as Specified in Its Charter) 1-2/F, Building 11, Zone 1 No.8 Life Science Parkway Ch |
|
| November 27, 2020 |
EX-99.1 Exhibit 99.1 Genetron Health Provides Update on HCCscreenTM for Liver Cancer Early Screening in China HCCscreenTM was selected by the National Cancer Center and the Wuxi municipal government for use in the “Liver Cancer Early Screening Comprehensive Prevention and Control Project”, a public health initiative Establishes joint venture with Wuxi municipal government; Expects the commercializ |
|
| November 9, 2020 |
Genetron Health Reports Third Quarter 2020 Unaudited Financial Results and Provides Business Update EX-99.1 Exhibit 99.1 Genetron Health Reports Third Quarter 2020 Unaudited Financial Results and Provides Business Update BEIJING, China, November 9, 2020 — Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostic |
|
| November 9, 2020 |
Current Report of Foreign Issuer - FORM 6-K Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2020 Commission File Number: 001-39328 Genetron Holdings Limited (Exact Name of Registrant as Specified in Its Charter) 1-2/F, Building 11, Zone 1 No.8 Life Science Parkway Ch |
|
| September 30, 2020 |
Exhibit 99.1 Genetron Health Receives U.S. FDA Breakthrough Device Designation for its Blood-based NGS Test for Early Detection of Hepatocellular Carcinoma Designation represents Genetron Health’s first step to potentially expand the geographical reach of HCCscreenTM BEIJING, CHINA and GAITHERSBURG, MARYLAND, September 30, 2020 (GLOBE NEWSWIRE) — Genetron Holdings Limited (“Genetron Health” or the |
|
| September 30, 2020 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2020 Commission File Number: 001-39328 Genetron Holdings Limited (Exact Name of Registrant as Specified in Its Charter) 1-2/F, Building 11, Zone 1 No.8 Life Science Parkway Changping |
|
| August 6, 2020 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a- 16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2020 Commission File Number: 001-39328 Genetron Holdings Limited (Exact Name of Registrant as Specified in Its Charter) 1-2/F, Building 11, Zone 1 No.8 Life Science Parkway Changping Di |
|
| August 6, 2020 |
Genetron Health Reports Second Quarter 2020 Unaudited Financial Results EX-99.1 2 a20-263391ex99d1.htm EX-99.1 Exhibit 99.1 Genetron Health Reports Second Quarter 2020 Unaudited Financial Results BEIJING, China, August 6, 2020 — Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq: GTH), a leading precision oncology company in China that specializes in offering molecular profiling tests, today announced its unaudited financial results for the second |
|
| June 22, 2020 |
424(B)(4) Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-234805 16,000,000 American Depositary Shares Genetron Holdings Limited Representing 80,000,000 Ordinary Shares This is an initial public offering of American depositary shares, or ADSs, representing ordinary shares of Genetron Holdings Limited. We are offering 16,000,000 ADSs. Each ADS represents of five our ordinary |
|
| June 18, 2020 |
Amendment No.3 to Form F-1 Table of Contents As filed with the Securities and Exchange Commission on June 18, 2020. Registration No. 333-234805 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Genetron Holdings Limited (Exact name of Registrant as specified in Its charter) Not Applicable (Tra |
|
| June 18, 2020 |
EX-10.23 Exhibit 10.23 *** CERTAIN MATERIAL (INDICATED BY THREE ASTERISKS IN BRACKETS) HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH (1) NOT MATERIAL AND (2) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Credit Agreement (for working capital loans not requiring a separate loan contract) No.: 2020 Financial Street Direct Grant 387 Grantor: China Merchants Bank, Beijing Branch (“Par |
|
| June 18, 2020 |
June 18, 2020 VIA EDGAR Mr. Ruairi Regan Ms. Brigitte Lippmann Division of Corporation Finance CF Office of Real Estate & Construction U.S. Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Re: Genetron Holdings Limited (CIK No. 0001782594) Registration Statement on Form F-1 (File No. 333-234805) Registration Statement on Form 8-A (File No. 001-39328) Ladies and Gentlemen: |
|
| June 18, 2020 |
FREE WRITING PROSPECTUS Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Registration No. |
|
| June 18, 2020 |
New York Northern California Washington DC S?o Paulo London Paris Madrid Hong Kong Beijing Tokyo Resident Hong Kong Partners Davis Polk & Wardwell Hong Kong Solicitors The Hong Kong Club Building 3A Chater Road Hong Kong 852 2533 3300 tel Karen Chan ? Yang Chu ? James C. |
|
| June 18, 2020 |
EX-10.21 Exhibit 10.21 *** CERTAIN MATERIAL (INDICATED BY THREE ASTERISKS IN BRACKETS) HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH (1) NOT MATERIAL AND (2) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Contract No.:0020000071-Year 2020 (Changping) No. 00109 Small Business Loan Agreement (2020 version) Important Notice: This Contract is entered into by the Parties in accordance w |
|
| June 18, 2020 |
EX-10.25 Exhibit 10.25 *** CERTAIN MATERIAL (INDICATED BY THREE ASTERISKS IN BRACKETS) HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH (1) NOT MATERIAL AND (2) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Collaboration Agreement Party A: iKang Guobin Healthcare Group, Inc. (“Party A”) Address: 603, Floor 6 (Floor 4-24), No.92 Jianguo Road, Chaoyang District, Chongqing Party B: Chon |
|
| June 18, 2020 |
EX-10.22 Exhibit 10.22 *** CERTAIN MATERIAL (INDICATED BY THREE ASTERISKS IN BRACKETS) HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH (1) NOT MATERIAL AND (2) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. RMB WORKING CAPITAL LOAN AGREEMENT Contact number: HTZ110660000LDZJ202000014 Borrower (Party A): Genetron Health (Beijing) Company, Ltd. Domicile: Room 201, 2/F, Building 11, Sect |
|
| June 18, 2020 |
Underwriters' Acceleration Request Credit Suisse Securities (USA) LLC Eleven Madison Avenue New York, NY 10010 United States of America China International Capital Corporation Hong Kong Securities Limited 29th Floor, One International Finance Centre 1 Harbour View Street Central, Hong Kong June 18, 2020 VIA EDGAR CORRESPONDENCE AND FACSIMILE Division of Corporation Finance U. |
|
| June 15, 2020 |
EX-10.25 Exhibit 10.25 *** CERTAIN MATERIAL (INDICATED BY THREE ASTERISKS IN BRACKETS) HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH (1) NOT MATERIAL AND (2) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Collaboration Agreement Party A: iKang Guobin Healthcare Group, Inc. (“Party A”) Address: 603, Floor 6 (Floor 4-24), No.92 Jianguo Road, Chaoyang District, Chongqing Party B: Chon |
|
| June 15, 2020 |
EX-10.21 Exhibit 10.21 *** CERTAIN MATERIAL (INDICATED BY THREE ASTERISKS IN BRACKETS) HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH (1) NOT MATERIAL AND (2) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Contract No.:0020000071-Year 2020 (Changping) No. 00109 Small Business Loan Agreement (2020 version) Important Notice: This Contract is entered into by the Parties in accordance w |
|
| June 15, 2020 |
EX-3.2 Exhibit 3.2 THE COMPANIES LAW (AS AMENDED) OF THE CAYMAN ISLANDS COMPANY LIMITED BY SHARES FOURTH AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION OF Genetron Holdings Limited 泛生子基因(控股)有限公司 (ADOPTED BY SPECIAL RESOLUTION PASSED ON JANUARY 14, 2020 AND EFFECTIVE CONDITIONAL AND IMMEDIATELY PRIOR TO THE COMPLETION OF THE COMPANY’S INITIAL PUBLIC OFFERING OF AMERICAN DEPOSITARY SHAR |
|
| June 15, 2020 |
Amendment No. 2 to Form F-1 Table of Contents As filed with the Securities and Exchange Commission on June 15, 2020. Registration No. 333-234805 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Genetron Holdings Limited (Exact name of Registrant as specified in Its charter) Not Applicable (Tr |
|
| June 15, 2020 |
Opinion of Davis Polk & Wardwell LLP regarding material U.S. federal income tax consequences EX-8.3 Exhibit 8.3 New York Northern California Washington DC São Paulo London Paris Madrid Tokyo Beijing Hong Kong Davis Polk & Wardwell LLP 450 Lexington Avenue New York, NY 10017 212 450 4000 tel 212 701 5800 fax June 15, 2020 Re: Registration Statement on Form F-1 1-2/F, Building 11, Zone 1, No.8 Life Science Parkway Changping District, Beijing, 102206 People’s Republic of China Dear Ladies an |
|
| June 15, 2020 |
New York Northern California Washington DC S?o Paulo London Paris Madrid Hong Kong Beijing Tokyo Resident Hong Kong Partners Davis Polk & Wardwell 852 2533 3300 tel Karen Chan ? Martin Rogers ? Hong Kong Solicitors Yang Chu ? Patrick S. |
|
| June 15, 2020 |
EX-10.23 Exhibit 10.23 *** CERTAIN MATERIAL (INDICATED BY THREE ASTERISKS IN BRACKETS) HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH (1) NOT MATERIAL AND (2) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Credit Agreement (for working capital loans not requiring a separate loan contract) No.: 2020 Financial Street Direct Grant 387 Grantor: China Merchants Bank, Beijing Branch (“Par |
|
| June 15, 2020 |
Exhibit 3.1 THE COMPANIES LAW OF THE CAYMAN ISLANDS EXEMPTED COMPANY LIMITED BY SHARES FOURTH AMENDED AND RESTATED MEMORANDUM OF ASSOCIATION OF Genetron Holdings Limited 泛生子基因(控股)有限公司 (Adopted by way of Special Resolutions passed on May 28, 2020) NAME 1. The name of the Company is Genetron Holdings Limited and its dual foreign name is 泛生子基因(控股)有限公司. REGISTERED OFFICE 2. The Registered Office of th |
|
| June 15, 2020 |
Form 8-A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Genetron Holdings Limited (Exact name of Registrant as specified in Its charter) Cayman Islands Not Applicable (State or other jurisdiction of incorporation or organization) (I.R.S. Employ |
|
| June 15, 2020 |
Exhibit 10.22 *** CERTAIN MATERIAL (INDICATED BY THREE ASTERISKS IN BRACKETS) HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH (1) NOT MATERIAL AND (2) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. RMB WORKING CAPITAL LOAN AGREEMENT Contact number: HTZ110660000LDZJ202000014 Borrower (Party A): Genetron Health (Beijing) Company, Ltd. Domicile: Room 201, 2/F, Building 11, Sector 1, No. |
|
| June 15, 2020 |
EX-10.24 Technical Service Contract CONFIDENTIAL INNOCARE Exhibit 10.24 *** CERTAIN MATERIAL (INDICATED BY THREE ASTERISKS IN BRACKETS) HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH (1) NOT MATERIAL AND (2) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Technical Service Contract Contract No.: Project Name: A Phase II, Multicenter, Single-Arm and Open Clinical Trial to Evaluate [** |
|
| June 15, 2020 |
Form of Underwriting Agreement EX-1.1 Exhibit 1.1 [●] American Depositary Shares Representing [●] Ordinary Shares, Par value US$0.00002 Per Share Genetron Holdings Limited UNDERWRITING AGREEMENT , 2020 Credit Suisse Securities (USA) LLC Eleven Madison Avenue New York, NY 10010 U.S.A. China International Capital Corporation Hong Kong Securities Limited 29th Floor, One International Finance Centre 1 Harbour View Street Central, H |
|
| June 4, 2020 |
New York Northern California Washington DC S?o Paulo London Paris Madrid Hong Kong Beijing Tokyo Resident Hong Kong Partners Davis Polk & Wardwell Hong Kong Solicitors The Hong Kong Club Building 3A Chater Road Hong Kong 852 2533 3300 tel Karen Chan ? Yang Chu ? James C. |
|
| June 4, 2020 |
EX-3.2 Exhibit 3.2 THE COMPANIES LAW (AS AMENDED) OF THE CAYMAN ISLANDS COMPANY LIMITED BY SHARES FOURTH AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION OF Genetron Holdings Limited 泛生子基因(控股)有限公司 (ADOPTED BY SPECIAL RESOLUTION PASSED ON JANUARY 14, 2020 AND EFFECTIVE CONDITIONAL AND IMMEDIATELY PRIOR TO THE COMPLETION OF THE COMPANY’S INITIAL PUBLIC OFFERING OF AMERICAN DEPOSITARY SHAR |
|
| June 4, 2020 |
Amendment No. 1 to Form F-1 Table of Contents As filed with the Securities and Exchange Commission on June 4, 2020. Registration No. 333-234805 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Genetron Holdings Limited (Exact name of Registrant as specified in Its charter) Not Applicable (Tra |
|
| June 4, 2020 |
EX-4.5 Exhibit 4.5 AMENDMENT TO AMENDED AND RESTATED SHAREHOLDERS AGREEMENT THIS AMENDMENT TO AMENDED AND RESTATED SHAREHOLDERS AGREEMENT (the “Amendment”) is an amendment to amend certain provisions of the Amended and Restated Shareholders Agreement dated November 19, 2019 (the “Restated Shareholders Agreement”). 1. Section 2.2 (a)(ii) of the Restated Shareholders Agreement shall be amended by de |
|
| June 4, 2020 |
EX-99.6 Exhibit 99.6 November 27, 2019 Genetron Holdings Limited (the “Company”) 1-2/F, Building 11, Zone 1, No.8 Life Science Parkway, Changping District Beijing 102206, People’s Republic of China Ladies and Gentlemen: Pursuant to Rule 438 under the Securities Act of 1933, as amended, I hereby consent to the reference of my name as a director of the Company, effective immediately upon the effecti |
|
| June 4, 2020 |
EX-4.6 Exhibit 4.6 AMENDMENT AGREEMENT TO AMENDED AND RESTATED SHAREHOLDERS AGREEMENT This Amendment Agreement to Amended and Restated Shareholders Agreement (this “Agreement”) is made and entered into as of May 28, 2020 by and among: 1. Genetron Holdings Limited (泛生子基因(控股)有限公司), an exempted company with limited liability organized and existing under the laws of the Cayman Islands (the “Company”); |
|
| June 4, 2020 |
EX-4.3 Exhibit 4.3 GENETRON HOLDINGS LIMITED AND THE BANK OF NEW YORK MELLON As Depositary AND OWNERS AND HOLDERS OF AMERICAN DEPOSITARY SHARES Deposit Agreement , 2019 TABLE OF CONTENTS ARTICLE 1. DEFINITIONS 1 SECTION 1.1. American Depositary Shares 1 SECTION 1.2. Commission 1 SECTION 1.3. Company 1 SECTION 1.4. Custodian 1 SECTION 1.5. Deliver; Surrender 1 SECTION 1.6. Deposit Agreement 2 SECTI |
|
| November 21, 2019 |
Principal Subsidiaries and the VIE of the Registrant EX-21.1 27 d779078dex211.htm EX-21.1 Exhibit 21.1 List of Principal Subsidiaries and the VIE of the Registrant Principal Subsidiaries Place of Incorporation Genetron Health (Hong Kong) Company Limited Hong Kong Genetron (Tianjin) Co., Ltd. PRC VIE Place of Incorporation Genetron Health (Beijing) Co., Ltd. PRC |
|
| November 21, 2019 |
Exhibit 10.18 Spouse Consent Letter To: Genetron (Tianjin) Co., Ltd. Whereas: 1. I, He Weiwu (ID card/passport number: [ ]), am the spouse of the natural person Wang Xiaoge (ID card number: [ ]). Wang Xiaoge holds 6.544% equity of Genetron Health (Beijing) Co., Ltd. (hereinafter referred to as ?Target Equity Interest?) 2. With respect to the aforementioned Target Equity Interest held by Wang Xiaog |
|
| November 21, 2019 |
Exhibit 10.12 SERIES D PREFERRED SHARES PURCHASE AGREEMENT THIS SERIES D PREFERRED SHARES PURCHASE AGREEMENT (the ?Agreement?) is made and entered into as of November 19, 2019 by and among: 1. Genetron Holdings Limited (?????????????), an exempted company with limited liability organized and existing under the laws of the Cayman Islands (the ?Company?); 2. Genetron Health (Hong Kong) Company Limit |
|
| November 21, 2019 |
New York Northern California Washington DC S?o Paulo London Paris Madrid Hong Kong Beijing Tokyo Resident Hong Kong Partners Davis Polk & Wardwell Hong Kong Solicitors The Hong Kong Club Building 3A Chater Road Hong Kong 852 2533 3300 tel William F. |
|
| November 21, 2019 |
Exhibit 10.4 EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”), dated as of [MONTH DATE], [YEAR] (the “Effective Date”), is entered between Genetron Holdings Limited, a company incorporated in the Cayman Islands (the “Company”) and [NAME] (the “Executive”). WHEREAS, the Company and the Executive wish to enter into an employment agreement whereby the Executive will be employed by the |
|
| November 21, 2019 |
Exhibit 10.15 Equity Interest Pledge Agreement This Equity Interest Pledge Agreement (hereinafter referred to as this ?Agreement?) has been executed by and among the following parties on July 30, 2019 in Beijing: Party A: Genetron (Tianjin) Co., Ltd., a limited liability company organized and existing under the PRC laws, with its address at Room 113(Deqing (Tianjin) Business Secretary Co., Ltd. No |
|
| November 21, 2019 |
Exhibit 3.2 THE COMPANIES LAW (AS AMENDED) OF THE CAYMAN ISLANDS COMPANY LIMITED BY SHARES FOURTH AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION OF Genetron Holdings Limited ?????(??)???? (ADOPTED BY SPECIAL RESOLUTION PASSED ON AND EFFECTIVE CONDITIONAL AND IMMEDIATELY PRIOR TO THE COMPLETION OF THE COMPANY?S INITIAL PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES REPRESENTING ITS ORDI |
|
| November 21, 2019 |
Exhibit 3.1 THE COMPANIES LAW OF THE CAYMAN ISLANDS EXEMPTED COMPANY LIMITED BY SHARES THIRD AMENDED AND RESTATED MEMORANDUM OF ASSOCIATION OF Genetron Holdings Limited ?????(??)???? (Adopted by way of Special Resolutions passed on November 19, 2019) NAME 1. The name of the Company is Genetron Holdings Limited and its dual foreign name is ?????(??)????. REGISTERED OFFICE 2. The Registered Office o |
|
| November 21, 2019 |
Exhibit 10.9 SHARE REPURCHASE AGREEMENT This SHARE REPURCHASE AGREEMENT (this ?Agreement?) is made and entered into as of October 1, 2019 by and among? (1) Genetron Holdings Limited (?????(??)????), an exempted company organized and existing under the laws of the Cayman Islands (the ?Company?)? (2) Each of the individuals as set forth in Part I of Schedule I attached hereto (the ?Individual Seller |
|
| November 21, 2019 |
Exhibit 10.8 SHARE REPURCHASE AGREEMENT This SHARE REPURCHASE AGREEMENT (this ?Agreement?) is made and entered into as of October 1, 2019 by and between Genetron Holdings Limited (?????(??)????), an exempted company organized and existing under the laws of the Cayman Islands (the ?Company?), and CrowdBees Holdings Limited, a company organized and existing under the laws of the British Virgin Islan |
|
| November 21, 2019 |
Exhibit 10.6 SHARE REPURCHASE AGREEMENT This SHARE REPURCHASE AGREEMENT (this ?Agreement?) is made and entered into as of October 1, 2019 by and between Genetron Holdings Limited (?????(??)????), an exempted company organized and existing under the laws of the Cayman Islands (the ?Company?), and EASY BENEFIT INVESTMENT LIMITED, a company organized and existing under the laws of the British Virgin |
|
| November 21, 2019 |
Code of Business Conduct and Ethics of the Registrant Exhibit 99.1 Genetron Holdings Limited (the ?Company?) Code of Business Conduct and Ethics Adopted November 20, 2019 Introduction This Code of Business Conduct and Ethics (the ?Code?) has been adopted by our Board of Directors (the ?Board?) and summarizes the standards that must guide our actions. Although they cover a wide range of business practices and procedures, these standards cannot and do |
|
| November 21, 2019 |
Exhibit 99.3 November 21, 2019 Genetron Holdings Limited 1-2/F, Building 11, Zone 1 No.8 Life Science Parkway Changping District, Beijing, 102206 People?s Republic of China +86 10 5090-7500 Re: Consent of Frost & Sullivan Ladies and Gentlemen, Reference is made to the registration statement on Form F-1 (the ?Registration Statement?) filed by Genetron Holdings Limited (the ?Company?) with the Unite |
|
| November 21, 2019 |
Exhibit 10.19 Spouse Consent Letter To: Genetron (Tianjin) Co., Ltd. Whereas: 1. I, Yan Shida (ID card number: [ ]), am the spouse of the natural person Wei Shuyan (ID card number: [ ]). Wei Shuyan holds 11.050% equity of Genetron Health (Beijing) Co., Ltd.( hereinafter referred to as “Target Equity Interest”); 2. With respect to the aforementioned Target Equity Interest held by Wei Shuyan, Wei Sh |
|
| November 21, 2019 |
Exhibit 10.3 FORM OF INDEMNIFICATION AGREEMENT GENETRON HOLDINGS LIMITED This Indemnification Agreement (this ?Agreement?), made and entered into as of the day of , 2019, by and between Genetron Holdings Limited, an exempted company with limited liability under the laws of Cayman Islands (the ?Company?) and (?Indemnitee?). W I T N E S S E T H: WHEREAS, highly competent persons have become more rel |
|
| November 21, 2019 |
Opinion of Shihui Partners regarding certain PRC tax matters (included in Exhibit 99.2) Exhibit 99.2 November 21, 2019 To: Genetron Holdings Limited??????(??)????? 1-2/F, Building 11, Zone 1, No.8 Life Science Parkway Changping District, Beijing, People?s Republic of China Dear Sirs or Madams, We are qualified lawyers of the People?s Republic of China (the ?PRC? or ?China?, for the purpose of this opinion only, the PRC shall not include the Hong Kong Special Administrative Region, th |
|
| November 21, 2019 |
EX-10.10 16 d779078dex1010.htm EX-10.10 Exhibit 10.10 SERIES C-2 PREFERRED SHARES PURCHASE AGREEMENT THIS SERIES C-2 PREFERRED SHARES PURCHASE AGREEMENT (the “Agreement”) is made and entered into as of October 1, 2019 by and among: 1. Genetron Holdings Limited (泛生子基因（控股）有限公司), an exempted company with limited liability organized and existing under the laws of the Cayman Islands (the “Company”); 2. |
|
| November 21, 2019 |
Powers of Attorney (included on signature page) Table of Contents As filed with the Securities and Exchange Commission on November 21, 2019. |
|
| November 21, 2019 |
Exhibit 99.4 November 20, 2019 Genetron Holdings Limited (the ?Company?) 1-2/F, Building 11, Zone 1, No.8 Life Science Parkway, Changping District Beijing 102206, People?s Republic of China Ladies and Gentlemen: Pursuant to Rule 438 under the Securities Act of 1933, as amended, I hereby consent to the reference of my name as a director of the Company, effective immediately upon the effectiveness o |
|
| November 21, 2019 |
EX-10.14 20 d779078dex1014.htm EX-10.14 Exhibit 10.14 Shareholder Voting Rights Entrustment Agreement This Shareholder Voting Rights Entrustment Agreement (hereinafter referred to as the “Agreement”) is signed among following Parties on July 30, 2019 in Beijing, the People’s Republic of China (the “PRC”). Party A： Genetron (Tianjin) Co., Ltd., a limited liability company, organized and existing un |
|
| November 21, 2019 |
Exhibit 10.16 Exclusive Option Agreement This Exclusive Option Agreement (this ?Agreement?) is executed by and among the following Parties on July 30, 2019 in Beijing, the People?s Republic of China (the ?PRC?): Party A: Genetron (Tianjin) Co., Ltd., a limited liability company, organized and existing under the laws of the PRC, with its address at Room 113(Deqing (Tianjin) Business Secretary Co., |
|
| November 21, 2019 |
Exhibit 10.20 *** CERTAIN MATERIAL (INDICATED BY THREE ASTERISKS IN BRACKETS) HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH (1) NOT MATERIAL AND (2) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. LICENSE AND SUPPLY AGREEMENT This LICENSE AND SUPPLY AGREEMENT (the ?Agreement?) is dated and effective January 1, 2018 (the ?Effective Date?), by and between Life Technologies Corporation |
|
| November 21, 2019 |
Exhibit 10.5 SHARES PURCHASE AGREEMENT THIS SHARES PURCHASE AGREEMENT (the ?Agreement?) is made and entered into as of July 2, 2019 by and among: 1. Genetron Holdings Limited (?????????????), an exempted company with limited liability organized and existing under the laws of the Cayman Islands (the ?Company?); 2. Genetron Health(Hong Kong) Company Limited (?????(??)???? ), a company organized and |
|
| November 21, 2019 |
Exhibit 4.4 AMENDED AND RESTATED SHAREHOLDERS AGREEMENT This Amended and Restated Shareholders Agreement (this ?Agreement?) is made and entered into as of November 19, 2019 by and among: 1. Genetron Holdings Limited (?????(??)????), an exempted company with limited liability organized and existing under the laws of the Cayman Islands (the ?Company?); 2. Genetron Health (Hong Kong) Company Limited |
|
| November 21, 2019 |
Exhibit 10.1 GENETRON HOLDINGS LIMITED RULES OF THE 2019 GENETRON HEALTH SHARE INCENTIVE PLAN Committee? Adoption: July 2, 2019 Expiry Date: July 1, 2029 Table of Contents Contents Page 1???Definitions 1 2???Granting Awards 3 3???Before Vesting 5 4???Vesting 6 5???Reduction or clawback of Awards 9 6???Leaving employment and death 10 7???Change of Control 11 8???Changing the Plan and termination 12 |
|
| November 21, 2019 |
EX-10.13 19 d779078dex1013.htm EX-10.13 Exhibit 10.13 Exclusive Business Cooperation Agreement This Exclusive Business Cooperation Agreement (this “Agreement”) is made and entered into by and between the following parties on July 2, 2019 in Beijing, the People’s Republic of China (“China” or the “PRC”). Party A: Genetron (Tianjin) Co., Ltd. Address: Room 113(Deqing (Tianjin) Business Secretary Co. |
|
| November 21, 2019 |
Exhibit 10.2 GENETRON HOLDINGS LIMITED RULES OF THE 2019 GENETRON HEALTH SHARE INCENTIVE SCHEME Committee’ Adoption: November 20, 2019 Expiry Date: November 19, 2029 Table of Contents Contents Page 1 Definitions 1 2 Granting Awards 3 3 Before Vesting 5 4 Vesting 6 5 Reduction or clawback of Awards 9 6 Leaving employment and death 10 7 Change of Control 11 8 Changing the Scheme and termination 12 9 |
|
| November 21, 2019 |
Exhibit 10.7 SHARE REPURCHASE AGREEMENT This SHARE REPURCHASE AGREEMENT (this ?Agreement?) is made and entered into as of October 1, 2019 by and between Genetron Holdings Limited (?????(??)????), an exempted company organized and existing under the laws of the Cayman Islands (the ?Company?), and Parkland Medtech Limited, an exempted company organized and existing under the laws of the Cayman Islan |
|
| November 21, 2019 |
Exhibit 4.2 Exhibit 4.2 Genetron Holdings Limited INCORPORATED IN THE CAYMAN ISLANDS UNDER THE COMPANIES LAW (AS Certificate Number AMENDED OR REVISED FROM TIME TO TIME) Number of Shares [ ? ] [ ? ] THE AUTHORISED CAPITAL OF THE COMPANY IS USD 50,000.00 DIVIDED INTO 2,500,000,000 ORDINARY SHARES OF PAR VALUE USD 0.00002 EACH THIS CERTIFIES THAT [ ? ] OF [ ? ] IS THE OWNER OF [ ? ] fully paid [ ? ] |
|
| November 21, 2019 |
EX-99.5 33 d779078dex995.htm EX-99.5 Exhibit 99.5 November 20, 2019 Genetron Holdings Limited (the “Company”) 1-2/F, Building 11, Zone 1, No.8 Life Science Parkway, Changping District Beijing 102206, People’s Republic of China Ladies and Gentlemen: Pursuant to Rule 438 under the Securities Act of 1933, as amended, I hereby consent to the reference of my name as a director of the Company, effective |
|
| November 21, 2019 |
Exhibit 10.11 AMENDMENT AGREEMENT TO SERIES C-2 PREFERRED SHARES PURCHASE AGREEMENT THIS AMENDMENT AGREEMENT TO SERIES C-2 PREFERRED SHARES PURCHASE AGREEMENT (the ?Agreement?) is made and entered into as of November 19, 2019 by and among: 1. Genetron Holdings Limited (?????????????), an exempted company with limited liability organized and existing under the laws of the Cayman Islands (the ?Compa |
|
| November 21, 2019 |
Exhibit 10.17 Spouse Consent Letter To: Genetron (Tianjin) Co., Ltd. Whereas: 1. I, Zhou Jing (ID card/passport number: [ ]), am the spouse of the natural person Wang Sizhen (ID card number: [ ]). Wang Sizhen holds 14.695% equity of Genetron Health (Beijing) Co., Ltd. (hereinafter referred to as ?Target Equity Interest?) 2. With respect to the aforementioned Target Equity Interest held by Wang Siz |
|
| October 11, 2019 |
Table of Contents This is a draft registration statement that is being confidentially submitted to the Securities and Exchange Commission on October 11, 2019. |
|
| October 11, 2019 |
EX-10.1 2 filename2.htm Exhibit 10.1 GENETRON HOLDINGS LIMITED RULES OF THE 2019 GENETRON HEALTH SHARE INCENTIVE PLAN Committee’ Adoption: July 2, 2019 Expiry Date: July 1, 2029 Table of Contents Contents Page 1 Definitions 1 2 Granting Awards 3 3 Before Vesting 5 4 Vesting 6 5 Reduction or clawback of Awards 9 6 Leaving employment and death 10 7 Change of Control 11 8 Changing the |
|
| October 11, 2019 |
DRSLTR New York Northern California Washington DC São Paulo London Paris Madrid Hong Kong Beijing Tokyo Resident Hong Kong Partners Davis Polk & Wardwell Hong Kong Solicitors The Hong Kong Club Building 3A Chater Road Hong Kong 852 2533 3300 tel William F. |
|
| September 3, 2019 |
Shareholder Voting Rights Entrustment Agreement EX-10.6 6 filename6.htm Exhibit 10.6 Shareholder Voting Rights Entrustment Agreement This Shareholder Voting Rights Entrustment Agreement (hereinafter referred to as the “Agreement”) is signed among following Parties on July 30, 2019 in Beijing, the People’s Republic of China (the “PRC”). Party A： Genetron (Tianjin) Co., Ltd., a limited liability company, organized and existing under the PRC laws, |
|
| September 3, 2019 |
Equity Interest Pledge Agreement Exhibit 10.7 Equity Interest Pledge Agreement This Equity Interest Pledge Agreement (hereinafter referred to as this ?Agreement?) has been executed by and among the following parties on July 30, 2019 in Beijing: Party A: Genetron (Tianjin) Co., Ltd., a limited liability company organized and existing under the PRC laws, with its address at Room 113(Deqing (Tianjin) Business Secretary Co., Ltd. No. |
|
| September 3, 2019 |
Exhibit 4.4 SHAREHOLDERS AGREEMENT This Shareholders Agreement (this ?Agreement?) is made and entered into as of July 2, 2019 by and among: 1. Genetron Holdings Limited (?????(??)???? ), an exempted company with limited liability organized and existing under the laws of the Cayman Islands (the ?Company?); 2. Genetron Health (Hong Kong) Company Limited (?????(??)???? ), a company organized and exis |
|
| September 3, 2019 |
Exhibit 10.9 Spouse Consent Letter To: Genetron (Tianjin) Co., Ltd. Whereas: 1. I, Zhou Jing (ID card/passport number: [ ]), am the spouse of the natural person Wang Sizhen (ID card number: [ ]). Wang Sizhen holds 14.695% equity of Genetron Health (Beijing) Co., Ltd. (hereinafter referred to as ?Target Equity Interest?) 2. With respect to the aforementioned Target Equity Interest held by Wang Sizh |
|
| September 3, 2019 |
EX-10.8 Exhibit 10.8 Exclusive Option Agreement This Exclusive Option Agreement (this “Agreement”) is executed by and among the following Parties on July 30, 2019 in Beijing, the People’s Republic of China (the “PRC”): Party A: Genetron (Tianjin) Co., Ltd., a limited liability company, organized and existing under the laws of the PRC, with its address at Room 113(Deqing (Tianjin) Business Secretar |
|
| September 3, 2019 |
Exclusive Business Cooperation Agreement EX-10.5 5 filename5.htm Exhibit 10.5 Exclusive Business Cooperation Agreement This Exclusive Business Cooperation Agreement (this “Agreement”) is made and entered into by and between the following parties on July 2, 2019 in Beijing, the People’s Republic of China (“China” or the “PRC”). Party A: Genetron (Tianjin) Co., Ltd. Address: Room 113(Deqing (Tianjin) Business Secretary Co., Ltd. No. 0720), |
|
| September 3, 2019 |
EX-10.1 3 filename3.htm Exhibit 10.1 GENETRON HOLDINGS LIMITED RULES OF THE 2019 GENETRON HEALTH SHARE INCENTIVE PLAN Committee’ Adoption: July 2, 2019 Expiry Date: July 2, 2019 Table of Contents Contents Page 1 Definitions 1 2 Granting Awards 3 3 Before Vesting 5 4 Vesting 6 5 Reduction or clawback of Awards 9 6 Leaving employment and death 10 7 Change of Control 11 8 Changing the |
|
| September 3, 2019 |
Table of Contents This is a draft registration statement that is being confidentially submitted to the Securities and Exchange Commission on September 3, 2019. |
|
| September 3, 2019 |
Exhibit 10.4 SHARES PURCHASE AGREEMENT THIS SHARES PURCHASE AGREEMENT (the ?Agreement?) is made and entered into as of July 2, 2019 by and among: 1. Genetron Holdings Limited (?????????????), an exempted company with limited liability organized and existing under the laws of the Cayman Islands (the ?Company?); 2. Genetron Health(Hong Kong) Company Limited (?????(??)???? ), a company organized and |
|
| September 3, 2019 |
DRSLTR New York Northern California Washington DC São Paulo London Paris Madrid Tokyo Beijing Hong Kong Resident Hong Kong Partners Davis Polk & Wardwell Hong Kong Solicitors The Hong Kong Club Building 3A Chater Road Hong Kong 852 2533 3300 tel 852 2533 3388 fax William F. |
|
| September 3, 2019 |
EX-10.11 11 filename11.htm Exhibit 10.11 Spouse Consent Letter To: Genetron (Tianjin) Co., Ltd. Whereas: 1. I, Yan Shida (ID card number: [ ]), am the spouse of the natural person Wei Shuyan (ID card number: [ ]). Wei Shuyan holds 11.050% equity of Genetron Health (Beijing) Co., Ltd.( hereinafter referred to as “Target Equity Interest”); 2. With respect to the aforementioned Target Equity Interest |
|
| September 3, 2019 |
Exhibit 10.10 Spouse Consent Letter To: Genetron (Tianjin) Co., Ltd. Whereas: 1. I, He Weiwu (ID card/passport number: [ ]), am the spouse of the natural person Wang Xiaoge (ID card number: [ ]). Wang Xiaoge holds 6.544% equity of Genetron Health (Beijing) Co., Ltd. (hereinafter referred to as ?Target Equity Interest?) 2. With respect to the aforementioned Target Equity Interest held by Wang Xiaog |
